Recombinant Human RXRA Protein, N-His from ProteoGenix; catalogue ARO-P12436; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human RXRA Protein, also known as Retinoid X Receptor Alpha, is a protein that plays a crucial role in regulating gene expression and cellular differentiation. It belongs to the nuclear receptor superfamily and is involved in various biological processes such as embryonic development, metabolism, and immune response. In this article, we will explore the structure, activity, and applications of this important protein.
The human RXRA gene is located on chromosome 9 and contains 9 exons. The protein is composed of 462 amino acids and has a molecular weight of approximately 52 kDa. It consists of several functional domains, including a DNA-binding domain, a ligand-binding domain, and a transactivation domain.
The DNA-binding domain is responsible for binding to specific DNA sequences, known as retinoid X response elements (RXREs), in the promoter regions of target genes. This allows the protein to regulate the expression of these genes. The ligand-binding domain, on the other hand, is responsible for binding to specific ligands, such as retinoic acid and other retinoids, which can modulate the activity of the protein. The transactivation domain is involved in recruiting coactivator proteins and initiating gene transcription.
As a nuclear receptor, RXRA functions as a transcription factor, meaning it can regulate the expression of genes by binding to specific DNA sequences. It forms heterodimers with other nuclear receptors, such as retinoic acid receptors (RARs) and vitamin D receptors (VDRs), to bind to RXREs and modulate gene expression.
RXRA has been shown to play a critical role in embryonic development, particularly in the development of the central nervous system, skeletal system, and immune system. It is also involved in regulating metabolism, including lipid and glucose metabolism, and has been linked to various diseases such as obesity, diabetes, and cancer.
Furthermore, RXRA has been found to have anti-inflammatory properties and can modulate the activity of immune cells, such as T cells and macrophages. This makes it a potential target for therapeutic interventions in autoimmune diseases and inflammatory disorders.
Recombinant Human RXRA Protein has various applications in both research and therapeutics. It is commonly used in studies involving retinoid signaling and gene regulation. It can also be used to investigate the role of RXRA in different biological processes, such as development, metabolism, and immunity.
In terms of therapeutics, RXRA has been identified as a potential target for the treatment of various diseases. For example, it has been shown to play a crucial role in the differentiation of adipocytes, and targeting RXRA may be a potential strategy for treating obesity and related metabolic disorders. In addition, RXRA agonists have been investigated for their potential anti-cancer effects, particularly in breast cancer and leukemia.
Moreover, recombinant RXRA protein can also be used as an antigen in vaccine development. It has been shown to induce immune responses and can be used as a target for developing vaccines against infectious diseases, such as tuberculosis and malaria.
Recombinant Human RXRA Protein is a crucial protein involved in various biological processes and has potential applications in both research and therapeutics. Its structure, activity, and applications make it a promising target for further studies and potential therapeutic interventions. As our understanding of this protein continues to evolve, we may uncover even more potential applications for this important molecule.
ProteoGenix catalogue number ARO-P12436. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 29.12 kDa; Fragment: Thr223-Thr462; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
